Non-BRCA1/2 Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer.

ABSTRACT:

Methods

Data were retrospectively collected from the registry of the High-Risk Breast and Ovarian Cancer Program at Clínica Las Condes, Santiago, Chile. Data captured included index case diagnosis, ancestry, family history, and genetic test results.

Results

Three hundred fifteen individuals underwent genetic testing during the study period. The frequency of germline pathogenic and likely pathogenic variants in a breast or ovarian cancer predisposition gene was 20.3%. Of those patients who underwent testing with a panel of both high- and moderate-penetrance genes, 10.5% were found to have pathogenic or likely pathogenic variants in non-BRCA1/2 genes.

Conclusion

Testing for non-BRCA1 and -2 mutations may be clinically relevant for individuals who are suspe

SUBMITTER: Adaniel C 

PROVIDER: S-EPMC6550094 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature